The test results from study of Rasagiline (also know as Agilect in the US or Azilect in Europe drug therapy useful in addressing the symptoms of Parkinson’s disease, show long term promise for patients. The results included a more than 20% improvement of the Uniform Parkinson’s Disease Rating Scale (UPDRS) scores in test patients over those taking a placebo. According to the article, Rasagiline will be available in the United States after it is approved by the Food and Drug Administration. You can read the news article about the study by
clicking here
Rasagiline is available in the UK and should be available in other European countries in coming months.
Click here for another news article.
For more information about Rasagiline
click here.
Or visit the information provided by the Teva Pharamceutical Industries, LTD, producers of Rasagiline, by
clicking here.
